Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?

NCT ID NCT05052528

Recruiting now ⭐️ CURE ⭐️ Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This phase I trial is testing different doses of chemotherapy given before a patient's own genetically modified immune cells (CAR T-cells) are infused to treat diffuse large B-cell lymphoma that has returned or not responded to prior treatment. The goal is to find the safest and most effective chemotherapy dose to prepare the body for the CAR T-cells, which are designed to recognize and kill cancer cells. The study involves adults whose commercial CAR T-cell therapy is not available, and it closely monitors side effects and treatment response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
chemotherapy (fludarabine and cyclophosphamide with or without rituximab) followed by CD19 chimeric antigen receptor (CAR) T-cell therapy
What this could lead to
If successful, this could help determine the best chemotherapy dose to prepare the body for CAR T-cell therapy, potentially improving outcomes for people with hard-to-treat lymphoma.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply broadly. There are risks of serious side effects from both the chemotherapy and the CAR T-cells, including infusion reactions and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California Davis Comprehensive Cancer Center

    RECRUITING

    Sacramento, California, 95817, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.